NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ALZN Stock Alerts $0.72 +0.02 (+2.86%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7450-Day Range$0.68▼$1.2052-Week Range$0.65▼$11.91Volume14,435 shsAverage Volume46,123 shsMarket Capitalization$4.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alzamend Neuro alerts: Email Address Alzamend Neuro MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.80Based on 4 Articles This WeekInsider TradingAcquiring Shares$994 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Alzamend Neuro. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.30% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently decreased by 67.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlzamend Neuro does not currently pay a dividend.Dividend GrowthAlzamend Neuro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALZN. Previous Next 2.7 News and Social Media Coverage News SentimentAlzamend Neuro has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Alzamend Neuro this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alzamend Neuro insiders have bought more of their company's stock than they have sold. Specifically, they have bought $994.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.86% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Alzamend Neuro is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alzamend Neuro is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlzamend Neuro has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Alzamend Neuro Stock (NASDAQ:ALZN)Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Read More ALZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALZN Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAlzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest UpdateApril 24, 2024 | msn.comAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are BuyingApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 17, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42March 26, 2024 | msn.comALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024February 24, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50February 13, 2024 | realmoney.thestreet.comMaxim gets more bearish on Alzamend Neuro, downgrades sharesFebruary 3, 2024 | msn.comAlzamend Neuro Risks Nasdaq Delisting Over Price DeficiencyApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.December 19, 2023 | markets.businessinsider.comBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market PotentialDecember 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024December 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024December 11, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsDecember 11, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next YearNovember 20, 2023 | marketwatch.comAlzamend Neuro Gets FDA Approval for Trial of Depression TreatmentNovember 20, 2023 | msn.comEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder StudyNovember 20, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNovember 16, 2023 | finance.yahoo.comAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNovember 13, 2023 | msn.comEXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug CandidateNovember 13, 2023 | finance.yahoo.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001November 2, 2023 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38October 30, 2023 | benzinga.comWhy Alzamend Neuro (ALZN) Stock Is Nosediving TodayOctober 30, 2023 | finance.yahoo.comAlzamend Neuro Announces Reverse Stock SplitOctober 25, 2023 | finance.yahoo.comAlzamend Neuro, Inc. (9ZT0.F)October 23, 2023 | businesswire.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001October 2, 2023 | msn.comEXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar DisorderOctober 2, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsSee More Headlines Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/27/2024Fiscal Year End4/30/2024Next Earnings (Estimated)7/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALZN CUSIPN/A CIK1677077 Webwww.alzamend.com Phone844-722-6303FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-612.26% Return on Assets-255.65% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book1.53Miscellaneous Outstanding Shares6,867,000Free Float6,121,000Market Cap$4.94 million OptionableOptionable Beta0.02 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Stephan Jackman (Age 47)CEO & Director Comp: $434.24kMr. David J. Katzoff (Age 61)Chief Financial Officer Comp: $116.67kMr. Milton Charles Ault III (Age 54)Founder & Vice Chairman Key CompetitorsSynaptogenixNASDAQ:SNPXBright Minds BiosciencesNASDAQ:DRUGGT BiopharmaNASDAQ:GTBPOragenicsNYSE:OGENKintara TherapeuticsNASDAQ:KTRAView All CompetitorsInsiders & InstitutionsMilton C Ault IIIBought 1,000 shares on 4/19/2024Total: $690.00 ($0.69/share)Milton C Ault IIIBought 334 shares on 4/1/2024Total: $303.94 ($0.91/share)Truist Financial CorpSold 2,160,580 shares on 2/2/2024Ownership: 2.168%Milton C Ault IIIBought 5,000 shares on 1/5/2024Total: $5,100.00 ($1.02/share)Milton C Ault IIIBought 500 shares on 12/26/2023Total: $450.00 ($0.90/share)View All Insider TransactionsView All Institutional Transactions ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed in 2024? Alzamend Neuro's stock was trading at $0.89 on January 1st, 2024. Since then, ALZN shares have decreased by 19.2% and is now trading at $0.7195. View the best growth stocks for 2024 here. Are investors shorting Alzamend Neuro? Alzamend Neuro saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 14,500 shares, a decline of 68.0% from the March 31st total of 45,300 shares. Based on an average daily volume of 55,500 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the shares of the company are short sold. View Alzamend Neuro's Short Interest. When is Alzamend Neuro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our ALZN earnings forecast. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings results on Monday, March, 25th. The company reported ($0.38) earnings per share (EPS) for the quarter. When did Alzamend Neuro's stock split? Alzamend Neuro's stock reverse split on Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALZN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
